Market Overview

Analysis: Positioning to Benefit within Associated Capital Group, SPAR Group, Aridis Pharmaceuticals, and Sonoma Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

Share:

NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Associated Capital Group, Inc. (NYSE:AC), SPAR Group, Inc. (NASDAQ:SGRP), Aridis Pharmaceuticals Inc. (NASDAQ:ARDS), and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

AC DOWNLOAD: http://Fundamental-Markets.com/register/?so=AC
SGRP DOWNLOAD: http://Fundamental-Markets.com/register/?so=SGRP
ARDS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARDS
SNOA DOWNLOAD: http://Fundamental-Markets.com/register/?so=SNOA

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Associated Capital Group, Inc. (NYSE:AC), SPAR Group, Inc. (NASDAQ:SGRP), Aridis Pharmaceuticals Inc. (NASDAQ:ARDS), and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ASSOCIATED CAPITAL GROUP, INC. (AC) REPORT OVERVIEW

Associated Capital Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Associated Capital Group reported revenue of $8.61MM vs $11.59MM (down 25.65%) and analysts estimated basic earnings per share -$1.76 vs $0.67. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Associated Capital Group reported revenue of $22.78MM vs $26.92MM (down 15.37%) and analysts estimated basic earnings per share -$2.52 vs $0.37. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Associated Capital Group, Inc. (AC) report, download it here: http://Fundamental-Markets.com/register/?so=AC

-----------------------------------------

SPAR GROUP, INC. (SGRP) REPORT OVERVIEW

SPAR Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, SPAR Group reported revenue of $57.00MM vs $50.02MM (up 13.95%) and analysts estimated basic earnings per share -$0.02 vs -$0.06. For the twelve months ended December 31st, 2018 vs December 31st, 2017, SPAR Group reported revenue of $229.19MM vs $181.38MM (up 26.36%) and analysts estimated basic earnings per share -$0.07 vs -$0.04. Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full SPAR Group, Inc. (SGRP) report, download it here: http://Fundamental-Markets.com/register/?so=SGRP

-----------------------------------------

ARIDIS PHARMACEUTICALS INC. (ARDS) REPORT OVERVIEW

Aridis Pharmaceuticals' Recent Financial Performance

For the twelve months ended December 31st, 2018 vs December 31st, 2017, Aridis Pharmaceuticals reported revenue of $2.76MM vs $0.86MM (up 220.58%) and analysts estimated basic earnings per share -$7.45 vs -$164.98. Analysts expect earnings to be released on June 27th, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is -$4.05 and is expected to report on March 26th, 2020.

To read the full Aridis Pharmaceuticals Inc. (ARDS) report, download it here: http://Fundamental-Markets.com/register/?so=ARDS

-----------------------------------------

SONOMA PHARMACEUTICALS, INC. (SNOA) REPORT OVERVIEW

Sonoma Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Sonoma Pharmaceuticals reported revenue of $5.28MM vs $4.84MM (up 9.02%) and basic earnings per share -$0.26 vs -$0.73. For the twelve months ended March 31st, 2018 vs March 31st, 2017, Sonoma Pharmaceuticals reported revenue of $16.66MM vs $12.83MM (up 29.89%) and analysts estimated basic earnings per share -$3.16 vs $2.20. Analysts expect earnings to be released on June 12th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.93.

To read the full Sonoma Pharmaceuticals, Inc. (SNOA) report, download it here: http://Fundamental-Markets.com/register/?so=SNOA

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Arden Dalio, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

View Comments and Join the Discussion!